GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » YoY EPS Growth

Ventyx Biosciences (Ventyx Biosciences) YoY EPS Growth : -27.42% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ventyx Biosciences YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Ventyx Biosciences's YoY EPS Growth for the quarter that ended in Dec. 2023 was -27.42%.

Ventyx Biosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.79.

Ventyx Biosciences YoY EPS Growth Historical Data

The historical data trend for Ventyx Biosciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ventyx Biosciences YoY EPS Growth Chart

Ventyx Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
- 38.69 -398.50 68.87 -59.42

Ventyx Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.14 -51.11 -133.33 -55.93 -27.42

Ventyx Biosciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Ventyx Biosciences's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-3.3--2.07)/ | -2.07 |
=-59.42 %

Ventyx Biosciences's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(-0.79--0.62)/ | -0.62 |
=-27.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ventyx Biosciences YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Ventyx Biosciences's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Ventyx Biosciences (Ventyx Biosciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ventyx Biosciences Inc (NAS:VTYX) » Definitions » YoY EPS Growth
Comparable Companies
KROS ARVN REPL ARDX TNGX RLAY SRRK NWBO PTGX MRVI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
662 Encinitas Boulevard, Suite 250, Encinitas, CA, USA, 92024
Website
https://www.ventyxbio.com
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Executives
Raju Mohan director, officer: Chief Executive Officer C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024
John Nuss officer: Chief Scientific Officer C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024
Christopher W Krueger officer: Chief Business Officer C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011
Nsv Partners Iii Lp 10 percent owner 500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830
Somu Subramaniam director, 10 percent owner C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Martin Auster officer: Chief Financial Officer C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
William J. Sandborn officer: See Remarks C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024
Sheila Gujrathi director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
William Richard White director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Allison Hulme director C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037
Venbio Global Strategic Fund Iii, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston director, 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116